

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/054575 A1

(51) International Patent Classification⁷: **A61K 31/41,**
31/196, A61P 9/00, 9/04

Victor [GB/GB]; 112 Banbury Road, Oxford OX2 6JU
(GB). PLAT, Francis, R. [FR/FR]; 16, rue Rév. Père Mus-
slin, F-68400 Riedisheim (FR).

(21) International Application Number:
PCT/EP2003/014406

(74) Agent: **GRUBB, Phillip**; Novartis AG, Corporate Intel-
lectual Property, CH-4002 Basel (CH).

(22) International Filing Date:
17 December 2003 (17.12.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ,
TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/434,250 18 December 2002 (18.12.2002) US

(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except AT, US*): **NO-
VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).

Published:

— with international search report

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH**
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CAMPION, Giles,**

(54) Title: COMBINATIONS OF VALSARTAN WITH COX-2 INHIBITORS

(57) **Abstract:** The invention relates a pharmaceutical composition comprising a combination of (i) the AT 1- receptor blocker val-
sartan or a pharmaceutically acceptable salt thereof and (ii) a COX-2 inhibitor or a pharmaceutically acceptable salt thereof and
optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or disease selected
from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunc-
tion and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation,
atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or
stable), renal insufficiency (diabetic and nondiabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary
and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma,
glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the manage-
ment of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive
dysfunction (such as Alzheimer's), glaucoma and stroke, comprising administering a therapeutically effective amount of the phar-
maceutical composition to a mammal in need thereof.